GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoMed Therapeutics Ltd (NAS:GDTC) » Definitions » Market Cap

CytoMed Therapeutics (CytoMed Therapeutics) Market Cap : $23.86 Mil (As of May. 28, 2024)


View and export this data going back to 2023. Start your Free Trial

What is CytoMed Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). CytoMed Therapeutics's share price for the quarter that ended in Dec. 2023 was $4.9. CytoMed Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 11.53 Mil. Therefore, CytoMed Therapeutics's market cap for the quarter that ended in Dec. 2023 was $56.49 Mil.

CytoMed Therapeutics's quarterly market cap increased from Dec. 2022 ($0.00 Mil) to Jun. 2023 ($35.16 Mil) and increased from Jun. 2023 ($35.16 Mil) to Dec. 2023 ($56.49 Mil).

CytoMed Therapeutics's annual market cap stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($56.49 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. CytoMed Therapeutics's Enterprise Value for Today is $17.53 Mil.


CytoMed Therapeutics Market Cap Historical Data

The historical data trend for CytoMed Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoMed Therapeutics Market Cap Chart

CytoMed Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Market Cap
- - - 56.49

CytoMed Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Market Cap Get a 7-Day Free Trial - - - 35.16 56.49

Competitive Comparison of CytoMed Therapeutics's Market Cap

For the Biotechnology subindustry, CytoMed Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoMed Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where CytoMed Therapeutics's Market Cap falls into.



CytoMed Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

CytoMed Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$4.9*11.5293
=$56.49

CytoMed Therapeutics's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=$4.9*11.5293
=$56.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CytoMed Therapeutics  (NAS:GDTC) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


CytoMed Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of CytoMed Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoMed Therapeutics (CytoMed Therapeutics) Business Description

Traded in Other Exchanges
Address
1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is majority revenue generator.
Executives
Chee Kong Choo director, 10 percent owner COMMONWEALTH LANE 08-22, SINGAPORE U0 149544
Jieming Zeng director, officer: CSO and CMO 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Shu Wang 10 percent owner 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Wee Kiat Tan director, officer: Chief Operating Officer 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Keng Kiat Toh director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Glorious Finance Ltd 10 percent owner 18 NAMLY GROVE SOUTH, SINGAPORE U0 267310
Luk Lucas Tien Wee director, officer: Chief Clinical Officer 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Leong Mark Kei Wei director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Chak Hua Yew director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yuin Han Loh director 1 COMMONWEALTH LANE 08-22, SINGAPORE U0 149544